多系统心血管代谢应激的分子特征及其与预后的关联
基于BPRHS和ARIC两个社区队列,研究者定义了多系统心血管代谢应激,鉴定出260种相关代谢物并构建简约代谢物评分,该评分在ARIC中与30年冠心病和全因死亡显著相关。
要点
- 多系统心血管代谢应激可由代谢物谱刻画,涉及氨基酸代谢、氧化应激和炎症等通路。
- 基于BPRHS构建的代谢物评分在ARIC中每升高1个标准差,冠心病风险HR 1.14,全因死亡HR 1.15。
- 代谢物评分与长期心血管预后独立相关,提示代谢功能障碍与心血管疾病共享分子病理生理。
核心结论
- 与心血管代谢应激相关的代谢物涉及已知和新型通路,并在30年时间范围内与冠心病和全因死亡相关。
研究设计与样本
- 前瞻性观察性队列研究,纳入BPRHS中668名有代谢物谱的波多黎各个体和ARIC中2152名有代谢物谱及长期随访的个体。
主要发现
- 在BPRHS中鉴定出260种与心血管代谢应激相关的代谢物,涉及氨基酸代谢、氧化应激和炎症等通路。
临床怎么用
- 代谢物评分可能有助于识别心血管代谢应激高负荷个体,为改善代谢功能障碍、心血管疾病和长寿相关预后提供干预靶点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Cardiometabolic disease is responsible for decreased longevity and poorer cardiovascular outcomes in the modern era. Metabolite profiling provides a specific measure of global metabolic function to examine specific metabolic mechanisms and pathways of cardiometabolic disease beyond its clinical definitions. OBJECTIVES: To define a molecular basis for cardiometabolic stress and assess its association with cardiovascular prognosis. DESIGN, SETTING, AND PARTICIPANTS: A prospective observational cohort study was conducted in a population-based setting across 2 geographically distinct centers (Boston Puerto Rican Health Study [BPRHS], an ongoing study of individuals enrolled between June 1, 2004, and October 31, 2009; and Atherosclerosis Risk in Communities [ARIC] study, whose participants were originally sampled between November 24, 1986, and February 10, 1990, and followed up through December 31, 2017). Participants in the BPRHS were 668 Puerto Rican individuals with metabolite profiling living in Massachusetts, and participants in the ARIC study were 2152 individuals with metabolite profiling and long-term follow-up for mortality and cardiovascular outcomes. Statistical analysis was performed from October 1, 2018, to March 13, 2020. EXPOSURE: The primary exposure was metabolite profiles across both cohorts. MAIN OUTCOMES AND MEASURES: Outcomes included associations with multisystem cardiometabolic stress and all-cause mortality and incident coronary heart disease (in the ARIC study). RESULTS: Participants in the BPRHS (N = 668; 491 women; mean [SD] age, 57.0 [7.4] years; mean [SD] body mass index [calculated as weight in kilograms divided by height in meters squared], 32.0 [6.5]) had higher prevalent cardiometabolic risk relative to those in the ARIC study (N = 2152; 599 African American individuals; 1213 women; mean [SD] age, 54.3 [5.7] years; mean [SD] body mass index, 28.0 [5.5]). Multisystem cardiometabolic stress was defined for 668 Puerto Rican individuals in the BPRHS as a multidimensional composite of hypothalamic-adrenal axis activity, sympathetic activation, blood pressure, proatherogenic dyslipidemia, insulin resistance, visceral adiposity, and inflammation. A total of 260 metabolites associated with cardiometabolic stress were identified in the BPRHS, involving known and novel pathways of cardiometabolic disease (eg, amino acid metabolism, oxidative stress, and inflammation). A parsimonious metabolite-based score associated with cardiometabolic stress in the BPRHS was subsequently created; this score was applied to shared metabolites in the ARIC study, demonstrating significant associations with coronary heart disease and all-cause mortality after multivariable adjustment at a 30-year horizon (per SD increase in metabolomic score: hazard ratio, 1.14; 95% CI, 1.00-1.31; P = .045 for coronary heart disease; and hazard ratio, 1.15; 95% CI, 1.07-1.24; P < .001 for all-cause mortality). CONCLUSIONS AND RELEVANCE: Metabolites associated with cardiometabolic stress identified known and novel pathways of cardiometabolic disease in high-risk, community-based cohorts and were associated with coronary heart disease and survival at a 30-year time horizon. These results underscore the shared molecular pathophysiology of metabolic dysfunction, cardiovascular disease, and longevity and suggest pathways for modification to improve prognosis across all linked conditions.
引用
- Murthy VL, Yu B, Wang W, et al. Molecular Signature of Multisystem Cardiometabolic Stress and Its Association With Prognosis. JAMA Cardiol. 2020. PMID: 32717046. doi:10.1001/jamacardio.2020.2686
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。